Daily FNArena News - Small Caps

As per the New Criterion’s Tim Boreham, Invion is an old company on a new mission

SiteMinder’s March quarter update showed the company is on track to reach positive earnings and cash flow next quarter and new product launches offer growth

The New Criterion’s Tim Boreham uncovers the potential of 4D Medical in the USA

Race Oncology tells a story all too familiar among developing Aussie biotechs, Tim Boreham reports

The New Criterion’s Tim Boreham explains the benefits of royalties and where to access them via the ASX

Tim Boreham highlights Hydrix as one of the most innovative small-cap healthcare companies on the ASX

Brokers welcome Life360’s new advertising initiative unveiled at the same time as FY23 results and FY24 guidance which both exceeded expectations

Capitol Health’s first half results exceeded brokers’ expectations with higher margins thanks largely to stringent cost control

Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter which others have debunked

Dicker data shares fell -10% yesterday but it had nothing to do with the company’s AI-fuelled outlook